Massachusetts Financial Services Co. MA increased its stake in shares of Arcus Biosciences, Inc. (NYSE:RCUS – Free Report) by 3.5% during the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 58,173 shares of the company’s stock after buying an additional 1,951 shares during the quarter. Massachusetts Financial Services Co. MA’s holdings in Arcus Biosciences were worth $886,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also recently modified their holdings of RCUS. GAMMA Investing LLC increased its position in Arcus Biosciences by 51.6% during the first quarter. GAMMA Investing LLC now owns 2,427 shares of the company’s stock worth $46,000 after purchasing an additional 826 shares during the last quarter. Headlands Technologies LLC acquired a new stake in shares of Arcus Biosciences during the 1st quarter worth about $59,000. Innealta Capital LLC purchased a new stake in Arcus Biosciences in the 2nd quarter valued at about $66,000. Quest Partners LLC acquired a new position in Arcus Biosciences in the fourth quarter valued at about $77,000. Finally, Cape Investment Advisory Inc. purchased a new position in Arcus Biosciences during the fourth quarter worth about $77,000. Institutional investors and hedge funds own 92.89% of the company’s stock.
Arcus Biosciences Stock Down 1.9 %
RCUS stock opened at $16.48 on Monday. The stock has a market cap of $1.51 billion, a price-to-earnings ratio of -5.30 and a beta of 0.90. Arcus Biosciences, Inc. has a fifty-two week low of $12.95 and a fifty-two week high of $20.48. The business has a 50 day moving average price of $16.07 and a 200 day moving average price of $16.21.
Analysts Set New Price Targets
A number of equities analysts recently weighed in on the stock. Evercore ISI raised shares of Arcus Biosciences to a “strong-buy” rating in a research report on Friday, August 9th. Barclays lowered their target price on Arcus Biosciences from $35.00 to $25.00 and set an “overweight” rating for the company in a report on Monday, July 8th. Truist Financial cut their price target on shares of Arcus Biosciences from $50.00 to $44.00 and set a “buy” rating on the stock in a research note on Monday, June 24th. Wedbush reiterated an “outperform” rating and issued a $30.00 price objective on shares of Arcus Biosciences in a research note on Friday, August 9th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Arcus Biosciences in a research report on Friday, August 9th. Seven research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Arcus Biosciences presently has a consensus rating of “Buy” and an average price target of $35.71.
View Our Latest Research Report on RCUS
Arcus Biosciences Company Profile
Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.
Featured Articles
- Five stocks we like better than Arcus Biosciences
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- 3 Stocks That Could Rise on European Bank Interest Rate Cuts
- Business Services Stocks Investing
- Take Advantage of Village Farms Stock as Cannabis Market Evolves
- 3 Grocery Stocks That Are Proving They Are Still Essential
- MarketBeat Week in Review – 9/16 – 9/20
Want to see what other hedge funds are holding RCUS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Arcus Biosciences, Inc. (NYSE:RCUS – Free Report).
Receive News & Ratings for Arcus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.